Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients

• Published in: Scientific reports 2020-10, Vol.10 (1), p.17774-17774, Article 17774
• Main Authors: Iborra, Marisa, García-Morales, Natalia, Rubio, Saoia, Bertoletti, Federico, Calvo, Marta, Taxonera, Carlos, Boscá-Watts, Marta Maia, Sierra, Mónica, Mancenido, Noemí, Beltrán, Belén, Nantes Castillejo, Óscar, García-Planella, Esther, Vera, Isabel, Alba, Cristina, Martí-Aguado, David, Ballester, María Pilar, Cano-Sanz, Noelia, Pajares-Villarroya, Ramón, Cerrillo, Elena, Cañada, Antonio, Nos, Pilar
• Format: Article
• Language: English
• Subjects: 692/4020/1503/257; 692/4020/1503/257/1389; 692/4020/1503/257/1402; Adult; Anti-Inflammatory Agents - therapeutic use; Antibodies, Monoclonal - therapeutic use; Cohort Studies; Colitis, Ulcerative - drug therapy; Colitis, Ulcerative - epidemiology; Female; Follow-Up Studies; Humanities and Social Sciences; Humans; Male; Medication Adherence; Middle Aged; multidisciplinary; Science; Science (multidisciplinary); Spain - epidemiology; Treatment Outcome; Tumor Necrosis Factor-alpha - antagonists & inhibitors
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-020-73577-0

Golimumab has demonstrated its long-term efficacy and safety in ulcerative colitis in clinical trials, but no data of long-term persistence has been published from real world. To estimate long-term persistence of golimumab, as well as factors associated with longer persistence, in patients with ulcerative colitis in real life. Observational multicentre study including adult patients with ulcerative colitis treated with golimumab and with at least twelve months of follow-up. We included 190 patients, 105 (55.26%) naive to anti-TNF, with mean disease duration of 9.32 ± 8.09 years. Probability of persistence was 63%, 46%, 39% and 27% at 1, 2, 3 and 4 years, respectively. Persistence was lower in patients with primary failure to previous anti-TNF. Eighty-two (43.16%) patients needed dose intensification during follow-up, with a mean time until intensification of 8.03 ± 8.64 months. Dose intensification and lower disease duration predicted higher persistence with golimumab (p = 0.037 and p = 0.008, respectively). During a follow-up of 17.25 ± 15.83 months, 32 (16.5%) patients needed hospitalisation and 11 (6%) underwent colectomy. No unexpected adverse events were reported. Golimumab has demonstrated good persistence and safety profile for long treatment in ulcerative colitis patients.